Sedation effect of rumezone for toluene sulfonate in patients with type A aortic dissection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048540

Enrollment

Unknown

Registered

2021-07-10

Start date

2021-07-30

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic dissection

Interventions

Experimental group:Remazolam tosylate combined with remifentanil hydrochloride

Control Group:Dexmedetomidine hydrochloride combined with remifentanil hydrochloride

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients after cardiopulmonary bypass for aortic dissection; 2. GCS score > 8 points; 3. CPOT score >= 3 points and RASS score >= 2 points; 4. Aged 18 to 75 years; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Severe, existing parenchymal liver disease with clinically significant portal hypertension, Child-Pugh C cirrhosis or acute liver failure; 3. Bronchial asthma or COPD, myasthenia gravis patients; 4. Patients with a history of alcohol or drug abuse; 5. Patients without sedation and analgesia; 6. MAP<55mmHg; 7. Receive 2 or more sedative or analgesic drugs within 24 hours; 8. Patients allergic to remazolam or remifentanil hydrochloride.

Design outcomes

Primary

Measure	Time frame
Richmond Agitation Sedation Scale;Criticalcare Pain Observation Tool;	—

Countries

China

Contacts

Public ContactShi Bolun

Henan Province Chest Hospital

65088797@qq.com+86 13673500996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026